Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMSC for Anastomotic Stenosis in Arteriovenous Fistula Creation
NCT04392206Phase 1Recruiting
- Start
- May 2020
- Primary completion
- Dec 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adipose derived mesenchymal stem cells in end stage renal disease (ESRD). Primary endpoint: Number of participants with treatment-related adverse events at 12 months. Started May 2020; status: recruiting.
02
Drugs
adipose derived mesenchymal stem cells
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT04392206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392206.